These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature. Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936 [TBL] [Abstract][Full Text] [Related]
4. Fusion protein from RGD peptide and Fc fragment of mouse immunoglobulin G inhibits angiogenesis in tumor. Li J; Ji J; Holmes LM; Burgin KE; Barton LB; Yu X; Wagner TE; Wei Y Cancer Gene Ther; 2004 May; 11(5):363-70. PubMed ID: 15044960 [TBL] [Abstract][Full Text] [Related]
5. Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile. Dreischalück J; Schwöppe C; Spieker T; Kessler T; Tiemann K; Liersch R; Schliemann C; Kreuter M; Kolkmeyer A; Hintelmann H; Mesters RM; Berdel WE Int J Oncol; 2010 Dec; 37(6):1389-97. PubMed ID: 21042706 [TBL] [Abstract][Full Text] [Related]
6. [Arginine-glycine-aspartic polypeptide mediated truncated tissue factor therapy for colorectal carcinoma]. Huang ZJ; Luo Q; Yan JH; Wang SY Zhonghua Wai Ke Za Zhi; 2010 Apr; 48(8):619-24. PubMed ID: 20646482 [TBL] [Abstract][Full Text] [Related]
7. Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice. Daei Farshchi Adli A; Jahanban-Esfahlan R; Seidi K; Farajzadeh D; Behzadi R; Zarghami N Adv Pharm Bull; 2021 Feb; 11(2):385-392. PubMed ID: 33880362 [No Abstract] [Full Text] [Related]
8. Targeting the vasculature of colorectal carcinoma with a fused protein of (RGD)₃-tTF. Huang ZJ; Zhao Y; Luo WY; You J; Li SW; Yi WC; Wang SY; Yan JH; Luo Q ScientificWorldJournal; 2013; 2013():637086. PubMed ID: 23861656 [TBL] [Abstract][Full Text] [Related]
9. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Bieker R; Kessler T; Schwöppe C; Padró T; Persigehl T; Bremer C; Dreischalück J; Kolkmeyer A; Heindel W; Mesters RM; Berdel WE Blood; 2009 May; 113(20):5019-27. PubMed ID: 19179306 [TBL] [Abstract][Full Text] [Related]
10. RGD and NGR modified TRAIL protein exhibited potent anti-metastasis effects on TRAIL-insensitive cancer cells in vitro and in vivo. Wang X; Qiao X; Shang Y; Zhang S; Li Y; He H; Chen SZ Amino Acids; 2017 May; 49(5):931-941. PubMed ID: 28236246 [TBL] [Abstract][Full Text] [Related]
11. Specific tissue factor delivery using a tumor-homing peptide for inducing tumor infarction. Shi Q; Zhang Y; Liu S; Liu G; Xu J; Zhao X; Anderson GJ; Nie G; Li S Biochem Pharmacol; 2018 Oct; 156():501-510. PubMed ID: 30222966 [TBL] [Abstract][Full Text] [Related]
12. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. Brand C; Schliemann C; Ring J; Kessler T; Bäumer S; Angenendt L; Mantke V; Ross R; Hintelmann H; Spieker T; Wardelmann E; Mesters RM; Berdel WE; Schwöppe C Oncotarget; 2016 Feb; 7(6):6774-89. PubMed ID: 26735180 [TBL] [Abstract][Full Text] [Related]
13. A novel CRAd in combination with cisplatin enhanced the antitumor efficacy in ovarian cancer. Zhang B; Liu Y; Zhang P; Wei Y; Yin X; Zheng J Int J Gynecol Cancer; 2011 Dec; 21(9):1540-6. PubMed ID: 22080895 [TBL] [Abstract][Full Text] [Related]
18. Dual function of RGD-modified VEGI-192 for breast cancer treatment. Wu J; Jiang Y; Yang W; He Z; Meng S; Zhang Q; Lin M; Zhang H; Li W; Yang Y; Jia Y; Qian L; Lu D; Cai W; Luo G; Wang Y; Zhu X; Li M Bioconjug Chem; 2012 Apr; 23(4):796-804. PubMed ID: 22455451 [TBL] [Abstract][Full Text] [Related]
19. Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide. Krais JJ; Virani N; McKernan PH; Nguyen Q; Fung KM; Sikavitsas VI; Kurkjian C; Harrison RG Mol Cancer Ther; 2017 Sep; 16(9):1855-1865. PubMed ID: 28522586 [TBL] [Abstract][Full Text] [Related]
20. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Hu P; Yan J; Sharifi J; Bai T; Khawli LA; Epstein AL Cancer Res; 2003 Aug; 63(16):5046-53. PubMed ID: 12941833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]